Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Income (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Non Operating Income for 16 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 15.29% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.5 million through Dec 2025, down 1.97% year-over-year, with the annual reading at -$28.5 million for FY2025, 1.97% down from the prior year.
  • Non Operating Income hit -$6.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$7.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $6.9 million in Q2 2023 to a low of -$10.7 million in Q2 2021.
  • Historically, Non Operating Income has averaged -$4.4 million across 5 years, with a median of -$6.2 million in 2024.
  • Biggest YoY gain for Non Operating Income was 517.38% in 2023; the steepest drop was 664.23% in 2023.
  • Year by year, Non Operating Income stood at -$10.3 million in 2021, then soared by 137.75% to $3.9 million in 2022, then plummeted by 285.26% to -$7.2 million in 2023, then decreased by 3.69% to -$7.5 million in 2024, then grew by 15.29% to -$6.4 million in 2025.
  • Business Quant data shows Non Operating Income for IRWD at -$6.4 million in Q4 2025, -$7.5 million in Q3 2025, and -$7.5 million in Q2 2025.